Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.526 -0.044 (-2.78%)
Streaming Delayed Price Updated: 10:20 AM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70,333
Open 1.550
Bid (Size) 1.520 (400)
Ask (Size) 1.530 (100)
Prev. Close 1.570
Today's Range 1.520 - 1.600
52wk Range 1.330 - 4.200
Shares Outstanding 31,056,238
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire

Performance

YTD
-53.6%
-53.6%
1 Month
-2.2%
-2.2%
3 Month
-17.0%
-17.0%
6 Month
-13.8%
-13.8%
1 Year
-34.8%
-34.8%

More News

Read More
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Inhibikase Posts Wider Loss in Q2 ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Announces Expansion of Senior Leadership Team
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
Via Benzinga
News headline image
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Inhibikase Therapeutics, Inc. - Common Stock publicly traded?
Yes, Inhibikase Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Inhibikase Therapeutics, Inc. - Common Stock trade on?
Inhibikase Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock?
The ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock is IKT on the Nasdaq Stock Market
What is the current price of Inhibikase Therapeutics, Inc. - Common Stock?
The current price of Inhibikase Therapeutics, Inc. - Common Stock is 1.526
When was Inhibikase Therapeutics, Inc. - Common Stock last traded?
The last trade of Inhibikase Therapeutics, Inc. - Common Stock was at 11/26/25 10:20 AM ET
What is the market capitalization of Inhibikase Therapeutics, Inc. - Common Stock?
The market capitalization of Inhibikase Therapeutics, Inc. - Common Stock is 47.40M
How many shares of Inhibikase Therapeutics, Inc. - Common Stock are outstanding?
Inhibikase Therapeutics, Inc. - Common Stock has 47M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.